Consensus CONMED Corporation

Stocks

CNMD

US2074101013

Medical Equipment, Supplies & Distribution

Market Closed - NYSE Other stock markets 16:00:02 2026-07-01 EDT			5-day change	1st Jan Change
32.76 ^USD	+0.09%		-7.46%	-19.31%

06-29	CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says	MT
06-29	BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target	MT

Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

839132b51f1ef3bf1bffdd2c38063.PJHMTG7Mbfuyi9kj5RRIMNibHnoFOos3AWQwNyurM9A.a9a8Aj-ODIyB7O4V3CQSf-vELCJ2Q-FWSQtSBnLJdLpWwa0HHqEXkYHEmA~872548549853e04fca6c6a6a8cb281e7

Analysts' recommendations: CONMED Corporation

06-29	CONMED Lagging Medtech Peers as Growth Slows, BofA Securities Says	MT
06-29	BofA Downgrades CONMED to Underperform From Neutral, Keeps $40 Price Target	MT
05-18	BofA Securities Adjusts CONMED Price Target to $40 From $52	MT
03-17	Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55	MT
25-06-12	Conmed Shares Fall After Needham Downgrade	MT
25-06-12	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT
25-04-28	Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	MT
25-02-06	JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	MT
24-08-01	Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating	MT
24-07-25	Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating	MT
24-04-25	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
24-04-25	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT
24-02-01	Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	MT
24-02-01	JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	MT
23-10-27	Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	MT
23-10-26	Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	MT
23-07-27	Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	MT
23-07-27	Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	MT
23-06-05	Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	MT
23-05-22	CL King Starts CONMED at Buy With $140 Price Target	MT
23-04-27	Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	MT
23-04-27	Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	MT
23-04-27	Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	MT
23-04-27	Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	MT
23-03-27	CONMED Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $124; Firm Sees Financial Profile Improving	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
CONMED CORPORATION	-	+20.88%
ABBOTT LABORATORIES		+26.62%
MEDTRONIC PLC		+23.45%
CENCORA, INC.		+21.7%
HOYA CORPORATION		+17.27%
BECTON, DICKINSON AND COMPANY		+16.25%
MEDLINE INC.		+22.57%
DEXCOM, INC.		+23.79%
WEST PHARMACEUTICAL SERVICES, INC.		-1.7%
STERIS PLC		+20.99%
Average		+19.18%
Weighted average by Cap.		+21.64%